 |
VasoMedical to Attend the Great Wall International Congress of Cardiology & Asia Pacific Heart Congress 2013 in Beijing |
EECP® Therapy Symposium Included In The Program at Prestigious Cardiology Conference in China
September 25, 2013 - WESTBURY, N.Y. - VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® Therapy systems, the gold standard of ECP therapy, announced today that the Company will participate in The 24th Great Wall International Congress of Cardiology & Asia Pacific Heart Congress (GW-ICC & APHC). The conference will take place from October 10-13, 2013 at the China National Convention Center in Beijing, The People's Republic of China.
During the Great Wall International Congress of Cardiology & Asia Pacific Heart Congress, leading cardiologists and other healthcare professionals from across the Asia Pacific region and beyond will share scientific information, best practice as well as learn and discuss new trends and developments in the field of cardiovascular medicine. In recent years the conference has attracted more than 13,000 attendees from 29 countries and regions. The GW-ICC & APHC is China's elite and largest cardiology conference and has hosted more than 1,500 academic speakers, 316 sessions and 45 special topics.
This year, as part of the scientific program for the GW-ICC & APHC, the 3rd International Enhanced External Counterpulsation (EECP®) Symposium will be held on October 12, 2013. EECP® Therapy experts from the US, China, Europe, India, the Middle East and other countries and regions will share their knowledge and experience in EECP® Therapy with the participants in the symposium. The speakers will also discuss other potential applications of EECP® such as in diabetes, stroke and cardiac rehabilitation. In addition, the International EECP® Society (IEECPS), an international association of physicians, and clinicians involved in the research, application and provision of EECP Therapy, will be launched at the EECP® symposium.
“As we are preparing to re-enter the Chinese market after over 10 years of absence, this year's Great Wall International Congress of Cardiology & Asia Pacific Heart Congress is of particular importance. This conference, and the EECP® symposium, also provides a platform to educate and generate awareness of EECP® Therapy in the Asia Pacific region, where we currently do business and where we see a great deal of potential growth in the future,” said Dr. Jun Ma, Chief Executive at VasoMedical. “We have been on a mission to educate the professionals and the public about the positive impacts EECP® Therapy on patient's life, and through this conference, we will once again be able to engage in dialogue with a large international cardiology community, which we trust will facilitate greater acceptance of the therapy within the medical communities around the world.”
Dr. John CK Hui, co-Chairman of the Organizing Committee for the 3rd International EECP® Symposium and EECP@GW-ICC2013, said, “The proposed mission of the IEECPS is to promote excellence in the noninvasive treatment of cardiovascular diseases through physician education, research, increased patient awareness, representation and the advancement of quality patient care with EECP® Therapy. We look forward to our official launch and foresee great potential for the impact this new professional society will have on acceptance of this therapy and, as a result, improve patients' quality of life globally.”
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contact:
Samantha Wolf / Andrew Herweg
KCSA Strategic Communications
212-896-1220 / 212-896-1273
swolf@kcsa.com / aherweg@kcsa.com